Latest Corporate Leadership News

Page 1 of 37
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
Terragen has completed the induction of 10,600 cattle into its largest feedlot trial and secured Brazilian approval for its probiotic feed additive. But customer receipts fell to $255,000 for the September quarter, while cash declined to $5.73 million amid a CEO departure and chair transition.
Ada Torres
Ada Torres
30 Oct 2026
Deterra Royalties has added a sizeable future copper income stream through its US$74.15 million Santa Cruz royalty acquisition, even as September-quarter revenue fell 15% year on year. The portfolio is gaining depth, but its next growth phase depends on construction, financing and commissioning milestones still ahead.
Victor Sage
Victor Sage
29 Oct 2026
INOVIQ will restart its EXO-OC ovarian cancer program through a staged optimisation and verification process after an independent review found sample collection and handling were the main sources of variability. The company is targeting US laboratory-developed test readiness in the first half of 2028, while a leadership change adds another moving part.
Ada Torres
Ada Torres
29 Oct 2026
Locality Planning Energy has returned to statutory profit and sharply reduced borrowings, but its next test is converting a large contracted pipeline into active service points. The company has given no numerical FY2027 guidance and is operating under an interim leadership structure while it searches for a permanent CEO.
Maxwell Dee
Maxwell Dee
14 Oct 2026
COSOL’s revenue fell 15.6% in FY26 and the ASX-listed asset management technology company swung to a $4.0 million statutory loss after goodwill impairments. Management is betting that leaner operations, new transport contracts and AI-led services can restore profitable growth, but the recovery still needs to show up in revenue.
Victor Sage
Victor Sage
13 Oct 2026
49 Metals has elevated CEO Phil Carter to Managing Director while shifting Executive Director Oliver Kreuzer into a non-executive and consulting role. The restructure comes with A$265,000 in base pay for Carter and 5 million options exercisable at 25¢ and 30¢.
Maxwell Dee
Maxwell Dee
14 Sept 2026
Reedy Lagoon has secured a fully underwritten $1.8 million placement that would more than double its shares on issue, while related-party debt is shifted to an interest-free 24-month repayment plan. The recapitalisation also brings a leadership change, with Geof Fethers retiring as managing director and Ish Peries joining the board.
Maxwell Dee
Maxwell Dee
9 Sept 2026
Yandal Resources shakes up its leadership with the appointment of seasoned geologist Eduard Eshuys as Non-Executive Chair and the departure of CEO Chris Oorschot, signaling a pivotal moment as the company advances its gold exploration projects in Western Australia.
Maxwell Dee
Maxwell Dee
1 Sept 2026
Regener8 Resources appoints Dave Malesic as Managing Director and CEO, aiming to accelerate its Balkan exploration program and unlock value at the Srebrenica North Project.
Maxwell Dee
Maxwell Dee
1 Sept 2026
Encounter Resources has appointed Simon Hay as Non-Executive Chairman and promoted Will Robinson to Managing Director/CEO, aligning leadership with its expanding niobium and copper-gold projects. The company’s Aileron niobium resource surged 54% in 2026, underpinning development ambitions.
Maxwell Dee
Maxwell Dee
31 Aug 2026
NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.
Ada Torres
Ada Torres
25 Aug 2026

Browse the archive

Full archive